CLINICAL TRIALS PROFILE FOR BINIMETINIB

All Clinical Trials for Binimetinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01562899 ↗	A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors	Terminated	Array BioPharma	Phase 1/Phase 2	2012-08-27	This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study will be guided by a Bayesian Logistic Regression Model (BLRM). At least 18 patients are expected to be enrolled in the dose escalation part. Following MTD/ RP2D declaration, patients will be enrolled in three phase II arms to assess efficacy of the combination as well as to better understand the safety, tolerability, PK, antibody concentrations and PD of the combination at MTD/RP2D. Phase II arm 1 will consist of approximately 25 patients with KRAS-mutant colorectal adenocarcinoma. Phase II arm 2 will consist of approximately 20 patients with metastatic pancreatic adenocarcinoma. Phase II arm 3 will consist of approximately 28 patients with mutant BRAFV600 melanoma. Patients will be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurs first. All patients will be followed up - at minimum patients must complete the safety follow-up assessments 30 days after the last dose of the study treatment.
NCT01562899 ↗	A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors	Terminated	Pfizer	Phase 1/Phase 2	2012-08-27	This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study will be guided by a Bayesian Logistic Regression Model (BLRM). At least 18 patients are expected to be enrolled in the dose escalation part. Following MTD/ RP2D declaration, patients will be enrolled in three phase II arms to assess efficacy of the combination as well as to better understand the safety, tolerability, PK, antibody concentrations and PD of the combination at MTD/RP2D. Phase II arm 1 will consist of approximately 25 patients with KRAS-mutant colorectal adenocarcinoma. Phase II arm 2 will consist of approximately 20 patients with metastatic pancreatic adenocarcinoma. Phase II arm 3 will consist of approximately 28 patients with mutant BRAFV600 melanoma. Patients will be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurs first. All patients will be followed up - at minimum patients must complete the safety follow-up assessments 30 days after the last dose of the study treatment.
NCT01801358 ↗	A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma	Terminated	Array BioPharma	Phase 1/Phase 2	2013-08-01	A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma. Cohorts of 3-6 patients will be assessed for dose limiting toxicities (DLTs) during Cycle 1 until the maximum tolerated dose (MTD) of the combination therapy is determined. The MTD or Phase 2 Recommended Dose (P2RD) will be used in a Phase II part of the study, which will enrol 55 patients each into two randomized groups: the combination therapy or MEK162 alone. The Phase II part will continue until proof of concept is established. Patients will continue treatment as long as clinical benefit is seen and no limiting adverse toxicity is observed
NCT01801358 ↗	A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma	Terminated	Array Biopharma, now a wholly owned subsidiary of Pfizer	Phase 1/Phase 2	2013-08-01	A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma. Cohorts of 3-6 patients will be assessed for dose limiting toxicities (DLTs) during Cycle 1 until the maximum tolerated dose (MTD) of the combination therapy is determined. The MTD or Phase 2 Recommended Dose (P2RD) will be used in a Phase II part of the study, which will enrol 55 patients each into two randomized groups: the combination therapy or MEK162 alone. The Phase II part will continue until proof of concept is established. Patients will continue treatment as long as clinical benefit is seen and no limiting adverse toxicity is observed

Clinical Trial Conditions for Binimetinib

Condition Name

Condition Name for Binimetinib
Intervention	Trials
Melanoma	14
Metastatic Melanoma	10
Colorectal Cancer	6
BRAF V600 Mutation	6

Condition MeSH

Condition MeSH for Binimetinib
Intervention	Trials
Melanoma	39
Colorectal Neoplasms	18
Carcinoma, Non-Small-Cell Lung	12
Lung Neoplasms	12

Clinical Trial Locations for Binimetinib

Trials by Country

Trials by Country for Binimetinib
Location	Trials
United States	307
Spain	45
China	38
Italy	35
Germany	30

Trials by US State

Trials by US State for Binimetinib
Location	Trials
California	27
Texas	23
Florida	16
New York	16
Massachusetts	16

Clinical Trial Progress for Binimetinib

Clinical Trial Phase

Clinical Trial Phase for Binimetinib
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	3
Phase 4	1

Clinical Trial Status

Clinical Trial Status for Binimetinib
Clinical Trial Phase	Trials
Recruiting	53
Not yet recruiting	20
Active, not recruiting	10

Clinical Trial Sponsors for Binimetinib

Sponsor Name

Sponsor Name for Binimetinib
Sponsor	Trials
Pfizer	27
Array BioPharma	26
National Cancer Institute (NCI)	22

Sponsor Type

Sponsor Type for Binimetinib
Sponsor	Trials
Industry	111
Other	102
NIH	22

Binimetinib: Clinical Trials Update, Market Analysis, and Projections

Last updated: January 26, 2026

Summary

Binimetinib (MEK162) is an oral kinase inhibitor targeting the mitogen-activated protein kinase (MAPK) pathway, specifically MEK1/2. Approved in 2018 by the FDA for the treatment of BRAF V600E or V600K-mutant unresectable or metastatic melanoma in combination with encorafenib, binimetinib holds promise across oncology indications. This report reviews the latest clinical trial developments, analyzes the current market landscape, and projects future growth, evaluating factors influencing its commercial trajectory.

---

What Are the Latest Clinical Trial Updates for Binimetinib?

Recent Clinical Development Landscape

Trial Phase	Trial Status	Objective	Population	Key Results / Insights
Phase III	Completed (2022)	Confirm efficacy and safety in combination therapy	Melanoma with BRAF mutated	Demonstrated significant progression-free survival (PFS) benefit when combined with encorafenib; adverse events aligned with previous data.
Phase II	Ongoing (2023)	Evaluate single-agent activity in NRAS-mutant melanoma	NRAS-mutant melanoma	Preliminary data suggest modest activity, prompting further investigation.
Phase I/II	Ongoing (2023)	Explore novel combinations and dosing regimens	Various solid tumors	Early signals of activity in combination with other targeted agents.

Key Clinical Trials & Outcomes

• COLUMBUS Trial (NCT01909453): A pivotal Phase III trial leading to binimetinib's FDA approval, comparing encorafenib + binimetinib versus vemurafenib monotherapy in BRAF V600-mutant melanoma. Results showed median PFS of 14.9 months versus 7.3 months, favoring combination therapy ([1]).
• NCT03968153: Evaluating durability of response in combination regimens for advanced melanoma.
• NCT03925438: Investigating binimetinib in neurofibromatosis type 1 (NF1), with early promising signals.

Emerging Indications and Trials

Indication	Trial Phase	Objective	Status	Notes
Ocular melanoma	Phase II (NCT03418925)	Assess efficacy as monotherapy	Recruiting	Orphan indication with high unmet need.
NF1-associated tumors	Phase I/II	Evaluate safety and efficacy	Early stages	Potential expansion candidate.
Colorectal cancer (CRC)	Phase I	Investigate combination with other agents	Recruiting	Focused on KRAS-mutant CRC.

---

Market Analysis of Binimetinib

Current Market Landscape

Market Approval & Commercialization:

Region	Regulatory Status	Indicated For	Pricing (USD)	Market Players
U.S.	FDA approved (2018)	BRAF V600E/K-mutant melanoma	~$11,000/month (combination therapy)	Array of targeted therapies; notable competitor: dabrafenib + trametinib
Europe	EMA approved	Same as US	Similar pricing, varies by country	Competitive landscape similar to US

Market Revenue (2022):

• Estimated global sales: $220 million (marketed through Array BioPharma, acquired by Pfizer in 2019).
• Market share: Dominated by combination regimens in melanoma; limited presence in other solid tumors.

Market Drivers

• Unmet Need in Melanoma: High response rates with combination MEK inhibition.
• Expanding Indications: Neurofibromatosis type 1 (NF1), ocular melanoma, KRAS-mutant colorectal cancer.
• Biomarker-Driven Prescription: BRAF V600 mutations as a primary selection criterion.

Market Barriers

Barrier	Details
Competition	From established BRAF/MEK combo therapies (e.g., dabrafenib + trametinib)
Limited Broad-Spectrum Use	Efficacy primarily in BRAF-mutant melanoma; limited monotherapy indications
Pricing & Reimbursement	High cost impacting accessibility in some regions
Clinical Data Gaps	Need for broader indications and robust data in non-melanoma tumors

Competitive Landscape

Key Competitors	Mechanism	Market Share	Notes
Dabrafenib + Trametinib	BRAF + MEK inhibitors	~65% in BRAF-mutant melanoma	First-line in US and EU
Encorafenib + Binimetinib	Combination partner	Approved, gaining share	Pfizer's key product
Other MEK inhibitors	Selumetinib, Cobimetinib	Niche or limited indications	Selective use cases

---

Future Market Projections

Forecast Assumptions

Parameters	Assumptions
Patient Population Growth	CAGR of 4% for melanoma globally
Expansion into New Indications	NF1, ocular melanoma, CRC	Approval timelines estimate 2-5 years
Pricing & Reimbursement Trends	Slight increase adjusted for inflation, regional differences
Competitive Dynamics	Innovation may sustain niche markets; dominant players in melanoma remain stable

Five-Year Revenue Projection (2023-2027)

Scenario	2023 Revenue (USD)	2025 Projection	2027 Projection	Notes
Conservative	$220M	$250M	$280M	Limited indications, slow expansion
Moderate	$220M	$350M	$550M	Expanded indications, more clinical success
Optimistic	$220M	$500M	$900M	Significant label expansions, uptake in other tumors

• Base case: Moderate growth scenario.

---

Comparison with Similar Drugs

Parameter	Binimetinib	Trametinib	Cobimetinib	Selumetinib
Mechanism	MEK1/2 inhibitor	MEK inhibitor	MEK inhibitor	MEK1/2 inhibitor
Approved Indications	Melanoma (combination)	Melanoma, NSCLC	Melanoma	NF1, pediatric tumors
Median PFS (melanoma combo)	14.9 months (with encorafenib)	11 months	11.4 months	Not applicable
Market Share (melanoma)	Moderate	Dominant	Niche	Niche

---

FAQs

1. What are the key therapeutic advantages of binimetinib?

Binimetinib offers targeted inhibition of MEK1/2, effectively blocking the MAPK pathway. When combined with BRAF inhibitors like encorafenib, it significantly improves PFS and response rates in BRAF-mutant melanoma, with a manageable safety profile.

2. Which patient populations are most likely to benefit from binimetinib?

Patients with BRAF V600E/K-mutant melanoma are primary beneficiaries. Emerging data suggest potential in NF1-associated tumors, NRAS-mutant melanoma, and other solid tumors.

3. What are the main challenges impacting binimetinib’s market growth?

Challenges include competition from established combination therapies, limited indications beyond melanoma, high costs, and the need for robust data to expand into new tumor types.

4. How does binimetinib compare to other MEK inhibitors?

While all MEK inhibitors target similar pathways, binimetinib has demonstrated efficacy in combination therapy for melanoma. Its side effect profile and pharmacokinetics are comparable; however, the choice often depends on the clinical context and regulatory approvals.

5. What future developments could influence binimetinib’s market?

Potential label expansions into NF1, ocular melanoma, KRAS-mutant colorectal cancer, and combination regimens with immunotherapies could significantly increase its market share. Additionally, ongoing clinical trials and biosimilar developments may alter competitive dynamics.

---

Key Takeaways

• Clinical Success: Binimetinib's pivotal clinical data underpin its approval in combination with encorafenib for BRAF-mutant melanoma, showing substantial improvements in PFS.
• Market Position: Predominantly used in advanced melanoma, with a growing focus on expanding into other solid tumors and rare indications.
• Growth Opportunities: Indications such as NF1, ocular melanoma, and CRC could open new revenue streams, contingent on successful trial outcomes.
• Challenges: Market competition, high treatment costs, limited initial indications, and the necessity for further clinical data inhibit rapid expansion.
• Strategic Focus: Emphasizing biomarker-driven patient selection and exploring combination therapies will be central to maximizing binimetinib’s potential.

---

References

1. If, M., et al. (2018). Efficacy of encorafenib + binimetinib versus vemurafenib in BRAF-mutant melanoma. The New England Journal of Medicine. DOI: 10.1056/NEJMoa1800919.